Similar articles

• Octreotide--a synthetic somatostatin.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 1989 Jul 14;31(796):66-8. Med Lett Drugs Ther. 1989. PMID: 2567960 Clinical Trial. No abstract available.
• NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

  Gorden P, Comi RJ, Maton PN, Go VL. Gorden P, et al. Ann Intern Med. 1989 Jan 1;110(1):35-50. doi: 10.7326/0003-4819-110-1-35. Ann Intern Med. 1989. PMID: 2535688 Review.
• Clinical use of the somatostatin analog SMS 201-995 in endocrinology.

  Cozzi R, Liuzzi A, Dallabonzana D, Oppizzi G, Orlandi P, De Palo C, Petroncini MM, Piolini M, Chiodini PG. Cozzi R, et al. J Endocrinol Invest. 1988 Nov;11(10):737-40. doi: 10.1007/BF03350937. J Endocrinol Invest. 1988. PMID: 2852695 No abstract available.
• [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].

  Arnold R, Neuhaus C, Trautmann ME. Arnold R, et al. Dtsch Med Wochenschr. 1992 Jul 3;117(27):1067-71. doi: 10.1055/s-2008-1062412. Dtsch Med Wochenschr. 1992. PMID: 1352235 Review. German. No abstract available.
• Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.

  Wynick D, Bloom SR. Wynick D, et al. J Clin Endocrinol Metab. 1991 Jul;73(1):1-3. doi: 10.1210/jcem-73-1-1. J Clin Endocrinol Metab. 1991. PMID: 1646213 Review.